Form 4: Oscar Health CTO Sells $3.5M in Stock

Oscar Health's President of Technology and CTO, Mario Schlosser, reported the sale of 234,861 shares of Class A common stock in early January 2026, executed under a Rule 10b5-1 trading plan.

Summary

• Mario Schlosser, President of Technology & CTO and a Director of Oscar Health, Inc. [OSCR], reported transactions involving the company's stock.
• On January 2, 2026, Schlosser converted 59,800 shares of Class B common stock into Class A common stock.
• Also on January 2, 2026, he sold 137,933 shares of Class A common stock at a weighted average price of $15.02 per share, totaling approximately $2,071,798.66.
• On January 5, 2026, he converted an additional 86,893 shares of Class B common stock into Class A common stock.
• On the same day, January 5, 2026, he sold 96,928 shares of Class A common stock at a weighted average price of $15.64 per share, totaling approximately $1,516,090.72.
• All reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on September 23, 2025.
• Following these transactions, Schlosser directly beneficially owns 350,180 shares of Class A common stock and 1,532,293 shares of Class B common stock (convertible to Class A).
• He also indirectly holds Class B common stock through three family trusts, totaling 1,399,999 shares, over which he disclaims beneficial ownership except for his pecuniary interest.

Sentiment

Score: 5

Explanation: While significant insider sales occurred, they were executed under a pre-arranged 10b5-1 plan, which typically mitigates the negative sentiment associated with unplanned insider selling, leading to a neutral overall sentiment.

Positives

• Transactions were executed under a pre-arranged Rule 10b5-1 trading plan, adopted on September 23, 2025, indicating planned diversification rather than a reaction to recent events.

Negatives

• Significant insider sales totaling 234,861 shares of Class A common stock, valued at approximately $3.59 million, could be perceived negatively by investors.

Risks

• Insider sales, even when pre-planned, can sometimes be interpreted by the market as a lack of confidence in the company's near-term prospects, potentially leading to negative investor sentiment.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Mario Schlosser indirectly holds Class B common stock through the Noah Pizzo-Schlosser Dynasty Trust (333,333 shares), Pizzo-Schlosser Family Dynasty Trust (633,333 shares), and Siena Pizzo-Schlosser Dynasty Trust (333,333 shares). He disclaims beneficial ownership over these shares except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders may interpret the insider sales as a signal, potentially influencing short-term trading decisions.
• The pre-planned nature of the sales via a Rule 10b5-1 plan may reassure some investors that the transactions are for personal financial planning rather than a reaction to adverse company-specific news.

Key Dates

Keywords

Oscar Health, OSCR, Mario Schlosser, insider trading, Form 4, stock sale, CTO, Director, 10b5-1 plan, Class A common stock, Class B common stock, beneficial ownership